IO Biotech plans to meet with the FDA this fall to discuss the data from the phase 3 trial of Cylembio and determine next ...

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

According to SDIC Securities, the global AI-driven drug market has more than doubled since 2021, hitting $1.76 billion in ...

Q2 2025 Earnings Call Transcript August 14, 2025 Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is $-3 ...

HHS' decision "could stagnate research that has the potential to save millions of lives," writes Simon Williams.

Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...

BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Focused on Advancing NurOwn into Phase 3b ENDURANCE Trial BrainStorm ...

Cancer is not solely a disease of uncontrolled cell proliferation, but also one of immune system failure. The concept of cancer immunoediting—comprising the ...

SineuGene Therapeutics Co., Ltd. ('SineuGene'), clinical-stage biotechnology company that mainly focuses on gene therapies for neurological disorders, announced today that China's National Medical ...

Q2 2025 Earnings Call Transcript August 14, 2025Brainstorm Cell Therapeutics Inc. beats earnings expectations.